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Abstract
Background: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following
acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of
MACE in patients who participated in the nationwide ACS Israeli Surveys (ACSIS) and were treated on discharge with a
fibrate (mainly bezafibrate) and statin combination vs. statin alone.
Methods: The study population comprised 8,982 patients from the ACSIS 2000, 2002, 2004, 2006, 2008 and 2010 enrollment
waves who were alive on discharge and received statin. Of these, 8,545 (95%) received statin alone and 437 (5%) received
fibrate/statin combination. MACE was defined as a composite measure of death, recurrent MI, recurrent ischemia, stent
thrombosis, ischemic stroke and urgent revascularization.
Results: Patients from the combination group were younger (58.1611.9 vs. 62.9612.6 years). However, they had
significantly more co-morbidities (hypertension, diabetes), current smokers and unfavorable cardio-metabolic profiles (with
respect to glucose, total cholesterol, triglyceride and HDL-cholesterol). Development of MACE was recorded in 513 (6.0%)
patients from the statin monotherapy group vs. 13 (3.2%) from the combination group, p=0.01. 30-day re-hospitalization
rate was significantly lower in the combination group: 68 (15.6%) vs. 1691 (19.8%) of patients, respectively; p=0.03.
Multivariable analysis identified the fibrate/statin combination as an independent predictor of reduced risk of MACE with
odds ratio of 0.54, 95% confidence interval 0.32–0.94.
Conclusion: A significantly lower risk of 30-day MACE rate was observed in patients receiving combined fibrate/statin
treatment following ACS compared with statin monotherapy. However, caution should be exercised in interpreting these
findings taking into consideration baseline differences between our observational study groups.
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Introduction
Fibrates have been used for the treatment of dyslipidemia
(mainly hypertriglyceridemia and low level of HDL cholesterol) for
more than 30 years. Their efficacy in reduction of cardiovascular
events, particularly in individuals with significant elevations in
plasma triglycerides, appears to be well defined [1–7]. However,
the usefulness of this approach on the background of concomitant
statin treatment is unclear. The recently published ACCORD-
Lipid trial [8] did not support the addition of one of the fibrates
(fenofibrate) to statin therapy in the general population – except
for the subgroup of diabetic patients with significant atherogenic
dyslipidemia. The effect of the combination of other fibrates with
statin on major adverse cardiovascular events (MACE) is
unknown. Also, in contrast to statin monotherapy, there are
almost no data regarding the effect of fibrates in patients
immediately post acute coronary syndrome (ACS).
The main aim of this study was to investigate 30-day rate of
MACE in patients participated in the ACS Israeli Surveys (ACSIS)
treated on discharge with a fibrate/statin combination (mainly
bezafibrate/statin) vs. statin alone. In addition, 30-day re-
hospitalization and 1-year mortality rates were also evaluated. In
order to assess whether the association between the combined
fibrate/statin treatment and clinical outcomes persisted in diverse
categories of patients, 30-day MACE rate was determined
according to the pre-specified co-morbidities and metabolic status.
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Study population
Our patients have been drawn from the ACSIS 2000, 2002,
2004, 2006, 2008 and 2010 enrollment waves. Details of the Acute
Coronary Syndrome Israeli Survey (ACSIS) registry have been
previously reported [9]. In brief, the ACSIS Registry is a 2-month
nationwide survey conducted biennially that prospectively collects
data from all ACS admissions in all 25 coronary care units (CCU)
in Israel. Patient management was at the discretion of the
attending physicians. Eligibility for the study was validated before
discharge from the CCU. Discharge diagnoses were recorded as
determined by the attending physicians based on clinical,
electrocardiographic, and enzymatic criteria. Demographic,
historical and clinical data, including medical management, were
recorded on pre-specified forms by dedicated study physicians.
The Central Data Coordinating Center (based at the Sheba
Medical Center) was responsible for the collection of all case
report forms and the Israel Heart Society was responsible for
keeping the survey database. 30-day outcome rates and 1-year
mortality rate were ascertained by hospital chart review, telephone
contact and use of the Israeli National Population Registry.
From 2000 to 2010, 11538 consecutive patients with ACS were
included in six ACSIS-enrollment waves from the whole country.
Our study population comprised 8982 patients who were alive on
discharge from the hospital, received statin and for whom 30-day
MACE rate was available. Of these, 8545 (95%) patients received
statin alone and 437 (5%) received a combined fibrate/statin
treatment. In all but 2010 enrollment waves, 1-year follow-up was
completed (for 7243 patients).
Ethics Statement
This register-based analysis of pre-existing data was conducted
according to the principles expressed in the Declaration of
Helsinki. The ACSIS was approved by the ethical committee of
the Sheba Medical Center. All patients provided written informed
consent for the collection of data and subsequent analysis.
Endpoints and definitions
In our study we used pre-specified definitions of the ACSIS.
The diagnosis of diabetes was done by the attending physician
based on the reported history, medical records and/or for patients
with fasting blood glucose of $126 mg/dL (7 mmol/L) registered
twice or taking any type of pharmacologic antidiabetic treatment
prior to enrollment. The diagnosis of hypertension was done based
on the reported history, medical records and/or for patients with
blood pressure .140/90 mm Hg registered twice, or treatment
with antihypertensive drugs prior to enrollment.
Primary endpoint of our study was 30-day MACE rate which
was defined as a composite measure of 30-day all-cause mortality,
recurrent MI, recurrent ischemia, stent thrombosis, ischemic
stroke and urgent revascularization. Secondary endpoints were 30-
day re-hospitalization rate and 1-year all-cause mortality.
Fibrates and statins
In accordance with pre-specified ACSIS forms, data regarding
statins and fibrates were collected as the classes of the lipid-
lowering medications but not as the specific drugs. We performed
specific drugs evaluation among all 437 patients that received
fibrate/statin combination. Of them, 405 (92.7%) of patients
received bezafibrate, 10 (2.3%) received ciprofibrate and 1 (0.2%)
received gemfibrozil (this fibrate is not registered in Israel),
whereas in 21 (4.8%) of patients details regarding specific fibrate
were unavailable. In regard to statins, 155 (35.5%) of patients
received atorvastatin, 257 (58.8%) received simvastatin, 9 (2.1%)
received rosuvastatin, 2 (0.5%) received cerivastatin and also 2
(0.5%) received fluvastatin. In 12 (2.7%) of patients details
regarding specific statin were unavailable.
Statistical Analysis
Statistical analysis was performed using SAS statistical software
(version 8.2, SAS Institute, Cary, NC). Categorical variables were
expressed as percentage, and continuous variables were expressed
as mean 6 SD. Comparisons of variables were performed by Chi-
Square and Fisher’s exact test for categorical variables and by
unpaired ANOVA test for continuous variables. Survival curves
were derived using the Kaplan–Meier approach, and unadjusted
comparisons of survival curves were performed using the log-rank
test.
In order to determine whether the combination of fibrate &
statin vs. statin only treatment on discharge is an independent
explanatory variable for 30-day MACE, multivariable logistic
regression analysis was applied with adjustment for the following
pre-specified variables: age, gender, smoking status, hypertension,
diabetes. In addition, the propensity score analysis that includes
age, gender, smoking status, hypertension, diabetes, beta-blockers,
angiotensin converting enzyme inhibitors and insulin was also
calculated.
Interactions between the discharge treatment and potential
confounders (categorized by age,65, gender, triglycerides,200,
HDL,40, smoking status, presence of diabetes and hypertension)
were examined
Results are presented as odds ratio with the appropriate 95%
confidence interval. All tests were two-sided and p value,0.05 was
considered statistically significant.
Results
Our population was categorized into 2 groups: 1) patients
receiving on discharge statin monotherapy – 8545; and 2) patients
receiving on discharge combined fibrate/statin treatment – 437.
Baseline data
The main clinical and laboratory characteristics of patients are
presented in Tables 1 and 2. The majority of patients in both
groups were men. Patients from the combination group were
younger (58.1611.9 vs. 62.9612.6 years). However, they had
significantly more co-morbidities (hypertension, diabetes, current
smokers) and unfavorable cardio-metabolic profile (with respect to
glucose, total cholesterol, triglyceride and HDL-cholesterol levels).
Weight, body mass index and blood pressure were also
significantly higher in patients of the combination group.
No significant differences between the groups were found for
history of stroke, chronic renal failure, peripheral vascular disease
and in-hospital cardiac interventions.
Data regarding treatment with cardiovascular drugs among the
study groups are presented in Table 3. Antiplatelet drugs (aspirin
and clopidogrel), beta blockers and angiotensin converting enzyme
inhibitors were the most commonly used medications. The use of
nitrates, calcium antagonists and diuretics was relatively low. More
patients from the combination fibrate/statin group received beta
blockers, angiotensin converting enzyme inhibitors and insulin
than their counterparts. There were no significant differences in
the proportion of patients receiving other cardiovascular drugs.
Outcomes of the study population during follow-up
During the follow-up period of 30 days, development of MACE
was recorded in 527 patients: in 513 (6.0%) patients from the statin
Fibrate/Statin in Acute Coronary Syndrome
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35298monotherapy group vs. 14 (3.2%) from the combined fibrate/
statin group, p=0.01 (Table 4).
30-day re-hospitalization rate was also significantly lower in
patients from the combination group than in their counterparts
from the statin monotherapy group: 68 (15.6%) vs. 1691 (19.8%)
respectively, p=0.03.
Crude 1-year mortality rates in patients of the combination
fibrate/statin group tended to be lower than in their counterparts
of the statin monotherapy group, but this trend did not reach
statistical significance.
Kaplan-Meier analysis of 7243 patients from years 2000–2008
(Figure 1) showed that the cumulative probability of survival at 1-
year of follow-up (in accordance with the time of occurrence) was
numerically higher among patients who received combined
fibrate/statin therapy compared with patients who received statin
monotherapy, with early separation of event rates between the 2
treatment groups. However, possibly due to sample size limitations
related to the relatively low number of mortality events in patients
who received combined therapy, these findings did not reach
statistical significance (p log-rank=0.066 for the overall difference
during follow-up).
Multivariable analysis (Table 5) identified the combined fibrate/
statin treatment as an independent predictor of reduced risk of 30-
day MACE following ACS hospitalization with odds ratio (OR)
0.54 [95% confidence interval (CI) 0.32–0.94], corresponding to
46% lower risk. Other significant variables in our model associated
with independent risk of MACE during follow-up were female
gender and age ,65 years. Propensity score analysis has shown
results for the effect of the combined fibrate/statin treatment very
similar to the multivariable model: OR 0.57, CI 0.33–0.97.
In order to assess whether the association between the
combined fibrate/statin treatment and the reduction of MACE
immediately post ACS hospitalization persisted in diverse
categories of co-morbidities and metabolic status, 30-day MACE
rate was determined in patients according to gender, age, level of
HDL cholesterol, triglycerides, smoking status, presence of
diabetes and hypertension (Table 6 and Figure 2). The lower
30-day MACE rate was found in patients receiving combined
fibrate/statin treatment, regardless of gender, age, smoking status
and hypertension. The beneficial effect of the combined fibrate/
statin treatment was augmented in patients with diabetes, low
HDL cholesterol and high triglycerides level and was significantly
attenuated in patients without diabetes (p-value for combined
therapy-by- diabetes interaction=0.03). In patients with HDL
cholesterol $40 mg/dl and triglycerides ,200 mg/dl the bene-
ficial effect of the combination fibrate and statin was absent.
However, no statistically significant interactions were identified in
these subsets.
Discussion
The main finding of our study is lower risk of 30-day MACE
rate in the patients that received combined fibrate/statin
treatment following ACS compared with the statin monotherapy.
During this period re-hospitalization rate was also significantly
Table 1. Baseline characteristics and co-morbidities of the study population.
Characteristics Statin alone (n=8545) Fibrate/Statin (n=437) p value
Age (years) 62.9612.6 58.1611.9 ,0.0001
Body mass index (kg/m2) 27.564.3 29.564.7 ,0.0001
Weight (kg) 79.1614.3 85.4614.9 ,0.0001
Women (%) 1918 (23) 90 (21) 0.365
Hypertension (%) 4829 (57) 296 (68) ,0.0001
Diabetes (%) 2838 (33) 225 (52) ,0.0001
Current smokers (%) 3190 (38) 210 (48) ,0.0001
Past smokers (%) 1654 (20) 85 (20) 0.97
History of stroke 623 (7) 30 (7) 0.73
CRF 796 (9) 48 (11) 0.24
PVD 710 (8.3) 38 (8.7) 0.77
Data are number (%) of patients or mean 6 SD.
CRF - chronic renal failure, PVD - peripheral vascular disease.
doi:10.1371/journal.pone.0035298.t001
Table 2. In-hospital cardiac interventions and laboratory
values.
Characteristics Statin alone Fibrate/Statin p value
CABG 396/8526/(5) 17/437/(4) 0.46
PCI 5392/8242/(65.3) 278/419/(75) 0.65
Only angiography 1261/7027/(18) 71/365/(20) 0.47
Systolic blood pressure
(mmHg)
142.6628.3 146.1625.2 0.01
Diastolic blood pressure
(mmHg)
81.8616.4 84.1615.4 0.004
Heart rate (beats/min) 80.2620.0 79.1616.9 0.27
Glucose (mg/dl) 147.6673.7 168.2688.7 ,0.0001
Total cholesterol (mg/dl) 189.2646.2 203.2648.9 ,0.0001
HDL-cholesterol (mg/dl) 41.4612.7 34.768.4 ,0.0001
Triglycerides (mg/dl) 157.06127.2 361.56262.1 ,0.0001
Creatinine (mg/dl) 1.260.8 1.160.5 0.25
Data are number of patients/number of interventions/(%) for interventions or
mean 6 SD for laboratory values.
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervantion.
HDL - high density lipoproteins.
Conversion factors for SI units (from mg/dL to mmol/L): for triglyceride multiply
by (x) 0.01129, for cholesterol multiply by (x) 0.02586, for glucose multiply by
0.055, for creatinine multiply by (x) 88.4.
doi:10.1371/journal.pone.0035298.t002
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in patients from the combined fibrate/statin group tended to be
lower than in their counterparts from the statin monotherapy
group; however this trend did not reach statistical significance.
Statins use is clearly efficacious in the treatment and prevention
of coronary artery disease, particularly in ACS [10–15]. As a
result, currently nearly all patients with ACS receive prescriptions
for statin in developed countries, unless contraindicated. However,
despite of this almost ubiquitous use of statins, a significant
number of recurrent MACE still occur and many patients remain
at high residual cardiovascular risk. Due to their beneficial effects
on lipid metabolism (mainly a decrease in triglyceride and an
increase in HDL-cholesterol), fibrates are good potential candi-
dates for reducing this residual cardiovascular risk in patients with
atherogenic dyslipidemia. Currently only two fibrates (bezafibrate
and ciprofibrate) are registered in Israel; of them, bezafibrate is the
most widely prescribed fibrate which is used in the vast majority of
the cases.
Although less clinical interventional studies have been per-
formed with fibrates than with statins, the therapeutic benefit using
one of the three ‘‘major’’ fibrates (fenofibrate, bezafibrate and
gemfibrozil) was demonstrated among patients with high triglyc-
erides and low HDL-cholesterol. In contrast, in patients without
dyslipidemia the favorable effects of fibrates on the ‘‘hard’’
cardiovascular end points were absent and usually there were no
significant difference between fibrate and placebo groups [16]. For
example, in a meta-analysis of dyslipidemic subgroups from the
five main fibrates trials, a 35% RR reduction in cardiovascular
events was observed compared with a 6% RR reduction in those
not meeting dyslipidemic criteria [17]. As expected, in a so called
‘‘general population’’ – reflecting a blend of effects in patients with
and without atherogenic dyslipidemia [18] – the beneficial effect of
fibrate therapy was diluted, producing only a modest 10% RR
decrease in major cardiovascular events and a 13% RR reduction
in coronary events in the other meta-analysis [19].
Nevertheless, in a time of a near ubiquitous presence of statin
treatment in the patients with cardio-vascular atherosclerotic
diseases or high risk for them, an appropriate question is: ‘‘What is
the role of fibrates as an addition to statin-based therapy?’’ The
ACCORD Lipid study had shown in a prespecified subgroup
analysis (941 out of 5518 patients) that patients with atherogenic
dyslipidemia benefited from the addition of fenofibrate to
simvastatin. Among all other 4548 patients included in this
analysis (without atherogenic dyslipidemia) such rates were 10.1%
in both fenofibrate and placebo study groups [8].
In line with previous studies, our data suggest that the favorable
effect of fibrates added to statin is particularly noticeable in
patients with diabetes, low HDL cholesterol and high triglycerides
level. Therefore, in appropriate patients fibrates probably may
lead to cardiovascular risk reduction not only as monotherapy but
in combination with statins as well. On the other hand, in patients
without atherogenic dyslipidemia a beneficial effect of the
combined fibrate/statin treatment on 30-day MACE rate was
absent.
A meta-analysis by Briel et al. [20] suggested that simply
increasing the amount of circulating high density lipoprotein
cholesterol does not reduce the risk of coronary heart disease
events. This meta-analysis did not take into consideration the
specific sort of intervention that alters levels of high density
lipoprotein cholesterol. Obviously, different medications or life
style changes may have different impacts on cardiovascular risk.
Particularly, our group has shown previously using the Bezafibrate
Table 3. Distribution of cardiovascular drugs among the study patients (on discharge).
Drugs Statin alone (n=8545) Fibrate/Statin (n=437) p value
Aspirin (%) 97 96 0.7
Clopidogrel (%) 72 74 0.2
Beta blockers (%) 82 88 0.004
Nitrates (%) 20 17 0.24
Calcium channel blockers (%) 16 18 0.5
Diuretics (%) 21 22 0.9
Aldosterone antagonist (%) 6 6 0.7
Angiotensin converting enzyme inhibitors (%) 75 80 0.01
Angiotenesin receptor blockers (%) 8 11 0.2
Insulin (%) 7 13 ,0.0001
doi:10.1371/journal.pone.0035298.t003
Table 4. Outcomes of the study population during follow-up (crude data).
Outcomes Frequency Missing Statin alone (n=8545) Fibrate/Statin (n=437) p value
30-day MACE - 513 (6.0) 14 (3.2) 0.01
30-day re-hospitalization - 1691 (19.8) 68 (15.6) 0.03
1-year all-cause mortality 1739 377 (5.5) 11 (3.2) 0.07
Data are number of events/(%).
- The primary endpoint of this study was 30-day Major Adverse Coronary Events (MACE): all-cause mortality, recurrent MI, recurrent ischemia, stent thrombosis, ischemic
stroke, urgent revascularization during follow-up.
doi:10.1371/journal.pone.0035298.t004
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raising therapy with bezafibrate is associated with long-term
mortality reduction that may be related to the degree of HDL-C
response to treatment [21]. These results are consistent with the
similar analyses from the other fibrates studies [22,23]. Circulating
HDL particles are greatly heterogeneous with a very complex
metabolic profile. HDL-C measures the cholesterol content of
nascent HDL, HDL2, and HDL3 particles and is, therefore, a
crude marker of reverse cholesterol transport. There is a broad
agreement that reverse cholesterol transport, the process of
transporting excess cholesterol from the arterial wall’s foam
macrophages to the liver, bile, and feces is one of HDL’s
important antiatherogenic properties [24].
Also the triglyceride -rich environment has been shown to be
strongly associated with an atherogenic lipoprotein phenotype or
atherogenic dyslipidemia. The atherogenic, triglyceride -rich
lipoprotein environment is common to insulin resistance, obesity,
metabolic syndrome, prediabetes, diabetes and usually is associ-
ated with low high-density lipoprotein cholesterol (HDL-C) and
higher CVD risk [25]. Fibrates, in brief, via peroxisome
proliferator-activated receptors (PPAR)-a, mediate the transcrip-
tional regulation and expression of genes involved in lipid
metabolism reducing the generation of atherogenic remnants,
promotes b-oxidation of fatty acids and decrease fatty acid
synthase activities; increase lipolysis and plasma clearance of
atherogenic lipoproteins [7]. In patients with atherogenic
dyslipidemia (high triglycerides and low HDL-cholesterol) fibrates
were consistently associated with reduced risk of cardiovascular
events [16].
In contrast to statins, the impact of fibrates on cardiovascular
events in the setting of ACS is unclear. Only one small study
suggested that bezafibrate was associated with a lower incidence of
major cardiovascular events during hospitalization [26]. The role
of fibrates in the possible MACE reduction following ACS
hospitalization is unknown. Therefore, our data offer essential
insight on this gape of knowledge.
Figure 1. Kaplan-Meier curve of mortality rate during one year follow-up for 7243 patients from years 2000–2008 (combined
fibrate/statin therapy vs. statin monotherapy, p log-rank=0.066).
doi:10.1371/journal.pone.0035298.g001
Table 5. The applied model of multivariable logistic regression analysis of risk for 30-day MACE in patients immediately post acute
coronary syndrome.
Variables Odds Ratio 95% confidence interval p value
Combined fibrate/statin treatment 0.54 0.32–0.94 0.03
Diabetes Mellitus 1.18 0.98–1.43 0.08
Age ,65 years 0.59 0.48–0.73 ,0.001
Women 1.45 1.18–1.77 ,0.001
Hypertension 1.10 0.90–1.34 0.3
Current smokers 1.04 0.84–1.28 0.7
doi:10.1371/journal.pone.0035298.t005
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of HDL cholesterol, triglycerides, smoking status, presence of diabetes and hypertension.
doi:10.1371/journal.pone.0035298.g002
Table 6. Effect of combined fibrate/statin treatment vs. statin monoterapy on 30-day Major Adverse Coronary Events (MACE) in
risk subgroups: odds ratio and 95% confidence interval (CI).
Risk Subgroup Odds Ratio (95% CI) P-value for interaction
Gender
Men 0.48 (0.25–0.94) 0.7
Women 0.62 (0.25–1.57)
Age
Age ,65 years 0.51 (0.24–1.09) 0.6
Age $65 years 0.66 (0.31–1.43)
HDL-C
HDL-C ,40 (mg/dl) 0.53 (0.26–1.09) 0.2
HDL-C $40 (mg/dl) 1.08 (0.43–2.7)
Triglycerides
Triglycerides ,200 (mg/dl) 1.03 (0.45–2.36) 0.2
Triglycerides $200(mg/dl) 0.52 (0.24–1.14)
Atherogenic dyslipidemia (Triglycerides .200 & HDL-C,40) 0.18
Atherogenic dyslipidemia: yes 0.35 (0.16–0.75)
Atherogenic dyslipidemia: no 0.89 (0.41–1.93)
Smoking status
Current smokers 0.37 (0.14–1.0) 0.3
Non-smokers 0.66 (0.35–1.26)
Diabetes Mellitus
Diabetes: yes 0.23 (0.08–0.62) 0.03
Diabetes: no 0.87 (0.46–1.67)
Hypertension
Hypertension: yes 0.53 (0.29–0.98) 0.7
Hypertension: no 0.42 (0.13–1.32)
HDL-C - high density lipoproteins cholesterol.
doi:10.1371/journal.pone.0035298.t006
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Our study has several important limitations. Data regarding
alcohol consumption and medications dose and frequency were
not available.
Although the present study assessed the impact from addition of
fibrate to statin on clinical outcomes within a pre-specified setting
of prospective nationwide surveys, it was not a randomized
controlled trial and we cannot rule out other factors that could
have influenced the observed improvements in clinical outcomes.
It should be mentioned that the baseline characteristics of the two
study groups were different. Particularly, larger proportion of
patients in the combined therapy group had poorer lipid profile.
These systematic differences could lead to the observed differential
treatment effect.
Multivariable and interaction analyses were utilized for MACE
rate evaluation in an aim to address the lack of randomization and
baseline differences between groups that may confound the results.
However, caution should be used in interpreting our findings
which require confirmation in prospectively planned controlled
clinical trials. Furthermore, the lack of interaction in some subsets
that were assessed could be due to a relatively low number of
observed MACE cases.
In conclusion, a significantly lower risk of 30-day MACE rate
was observed in patients receiving combined fibrate/statin
treatment (mainly bezafibrate/statin combination) following ACS
compared with statin monotherapy, with a more pronounced
effect among those with diabetes.
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